Direct Inhibition of the N-Methyl-D-Aspartate Receptor

Total Page:16

File Type:pdf, Size:1020Kb

Direct Inhibition of the N-Methyl-D-Aspartate Receptor 1053 Anesthesiology 1999; 91:1053–63 © 1999 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Direct Inhibition of the N-methyl-D-aspartate Receptor Channel by High Concentrations of Opioids Tomohiro Yamakura, M.D.,* Kenji Sakimura, Ph.D.,† Koki Shimoji, M.D.‡ Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/91/4/1053/397882/0000542-199910000-00026.pdf by guest on 24 September 2021 Background: Electrophysiologic and receptor binding studies HIGH concentrations of various opioid agonists and an- showed that some opioids have noncompetitive N-methyl-D- tagonists protect neurons against central nervous system aspartate (NMDA) receptor antagonist properties. ischemia and injury and neurotoxicity of exogenously Methods: The effects and mechanisms of action of various 1–3 opioid compounds were examined on four kinds of hetero- applied N-methyl-D-aspartate (NMDA). More recent meric NMDA receptor channels, namely the e1/z1, e2/z1, e3/z1, electrophysiologic and receptor binding studies have and e4/z1 channels, expressed in Xenopus oocytes. Further- found that some opioid agonists, such as meperidine, more, the action sites of opioids on NMDA receptor channels methadone, and ketobemidone, reduce NMDA-induced were investigated by site-directed mutagenesis. depolarization in rat-brain slice preparations and inhibit Results: Meperidine inhibited four kinds of channels to a 3 similar extent with inhibitor concentrations for half-control [ H]MK-801 (dizocilpine) binding in rat cortical and fore- m 4–6 response (IC50s) of 210–270 M. Morphine, fentanyl, codeine, brain membranes. These studies suggest that some and naloxone also inhibited NMDA receptor channels with opioids have NMDA receptor antagonist properties. affinities comparable to meperidine. Opioid inhibition ex- However, it is uncertain whether the NMDA receptor hibited voltage dependence and was quite effective at nega- antagonist activity is a property common to various opi- tive potentials. Opioids also shifted the inhibition curve of Mg21 to the right. Furthermore, replacement of the con- oid compounds. In addition, mechanisms of NMDA re- served asparagine residue with glutamine in the channel- ceptor channel inhibition by opioids remain to be char- lining segment M2 of the z1 subunit, which constitutes the acterized. block sites of Mg21 and ketamine, reduced the sensitivity to Cloning and expression studies have revealed the mo- e opioids, whereas that of the 2 subunit barely affected the lecular heterogeneity of the NMDA receptor channel.7 opioid sensitivity. Conclusions: These results, together with previous findings, The mouse NMDA receptor channel is composed of at e z suggest that the low-affinity NMDA receptor antagonist activity least two families of subunits, the (rat NR2) and (rat is a common characteristic of various opioid compounds, and NR1) subfamilies of the glutamate receptor channel, that the inhibition is a result of channel-block mechanisms at which share amino acid sequence homology with the 21 the site, which partially overlaps with those of Mg and ket- subunits of the a-amino-3-hydroxy-5-methyl-4-isoxazole amine. This antagonist property of opioids may be clinically propionic acid (AMPA)– or kainate-selective glutamate significant in the spinal cord following epidural or intrathecal e z administration, after which the cerebrospinal fluid concentra- receptor channels. The functional properties of the / tions of some opioids reach the high micromolar level. (Key heteromeric NMDA receptor channels are determined words: Channel blocker; dissociative anesthetics; glutamate re- by the constituting e subunit species (e1–e4). The het- ceptor; subunit.) eromeric e1/z1, e2/z1, e3/z1, and e4/z1 channels exhibit different affinities for agonists and different sensitivities 21 * Instructor, Department of Anesthesiology. to Mg block and competitive and noncompetitive an- † Professor, Department of Cellular Neurobiology, Brain Research tagonists. The e1 and z1 subunit mRNAs are widely Institute. distributed in the brain, whereas the e2 subunit mRNA is ‡ Professor and Chairman, Department of Anesthesiology. expressed abundantly in the forebrain. The e3 subunit Received from the Departments of Anesthesiology and Cellular Neu- mRNA is predominantly found in the cerebellum, but the robiology, Niigata University School of Medicine, Niigata, Japan. Sub- e4 subunit mRNA is weakly expressed in the dienceph- mitted for publication January 19, 1999. Accepted for publication May alon and the brainstem. Reports on expression patterns 14, 1999. Supported by a grant-in-aid (no. 10671407) from the Japa- in the adult spinal cord are controversial. The z1, e1, and nese Ministry of Education, Science and Culture, Tokyo, Japan. e2 subunit mRNAs are the predominant transcripts de- Address reprint requests to Dr. Yamakura: Department of Anesthe- 8 z siology, Niigata University School of Medicine, 1-757 Asahimachi, Ni- tected in the mouse cervical cord, whereas the NR1- 1, igata 951-8510, Japan. Address electronic mail to: NR2C-e3, and NR2D-e4 subunit mRNAs are found in the [email protected] rat lumbar spinal cord.9 Anesthesiology, V 91, No 4, Oct 1999 1054 YAMAKURA ET AL. Fig. 1. Schematic representations of the proposed structure of glutamate receptor channel subunits. (A) Three transmem- brane segment topology model. (B) Amino acid sequences of segment M2 of the glutamate receptor channel subunits Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/91/4/1053/397882/0000542-199910000-00026.pdf by guest on 24 September 2021 selective for NMDA (e1, e2, e3, e4, and z1) and those selective for AMPA (a1, a2, a3, and a4). The box indicates the Q (glu- tamine)/R (arginine)/N (asparagine) site of the glutamate receptor channel sub- units, which determines the permeability and block by divalent cations. NMDA receptor channel subunits have four hydrophobic the e1/z1, e2/z1, e3/z1, and e4/z1 channels) were synthe- segments (M1–M4) within their central regions. According sized using pSPGRe1,13 pSPGRe2,14 pSPGRe3,15 to the three transmembrane segment model, segment M2 pSPGRe4,16 and pSPGRz1,15 respectively. The e2, e2- forms a reentrant membrane loop with both ends facing N589Q, z1, and z1-N598Q subunit-specific mRNAs (for the the cytoplasm, and the carboxyl-terminal region resides in expression of the e2-N589Q/z1, e2/z1-N598Q, and e2- the cytoplasm (fig. 1A).7 Site-directed mutagenesis has re- N589Q/z1-N598Q channels) were synthesized using vealed that the conserved asparagine (N) residues in seg- pBKSAe2,17 pBKSAe2-N589Q,11 pBKSAz1,18 and pBKSAz1- ment M2 of the e and z subunits govern both Mg21 block N598Q,11 respectively. The a1 and a2 subunit-specific mR- and Ca21 permeability of NMDA receptor channels, thus NAs for the a1/a2 AMPA-selective glutamate receptor indicating that segment M2 constitutes the ion-channel channel were synthesized using pSPGR1 and pSPGR2, re- pore of NMDA receptor channels.10,11 The position of this spectively.19 asparagine residue corresponds to that of glutamine (Q) or Xenopus laevis oocytes were injected with the wild- arginine (R) of the a subunits, which determines the Ca21 type or mutant e subunit–specific mRNA and the wild- permeability of the AMPA-selective glutamate receptor type or mutant z subunit–specific mRNA at a molar ratio channel 12 (fig. 1B). of 1:1, or with the a1 and a2 subunit–specific mRNAs at In the present investigation, we examined the effects a molar ratio of 10:1; the total amount of mRNAs injected and mechanisms of action of various opioid compounds per oocyte was approximately 0.6 ng for the e1/z1 and (phenylpiperidine derivatives meperidine and fentanyl, e2/z1 channels; 14 ng for the e3/z1 and e4/z1 channels; naturally occurring opioids morphine and codeine, and 4 ng for the e2-N589Q/z1, e2/z1-N598Q, and e2-N589Q/ opioid antagonist naloxone) on the e1/z1, e2/z1, e3/z1 z1-N598Q channels; and 10 ng for the a1/a2 channel. and e4/z1 heteromeric NMDA channels expressed in Xenopus oocytes. Furthermore, the action sites of opi- Electrophysiological Analyses oids on NMDA receptor channels were investigated by After incubation at approximately 19°C for 2 or 3 days, site-directed mutagenesis. whole-cell currents evoked by bath application of ago- nists for approximately 15 s were recorded at 270 mV membrane potential with a conventional two-micropi- Materials and Methods pette voltage clamp.19 The current responses of the wild-type and mutant e/z channels to 10 mML-glutamate Subunit-specific mRNA Preparation and Expression plus 10 mM glycine (almost saturating concentrations for in Xenopus Oocytes all e/z channels) were measured in Ba21-Ringer’s solu- Subunit-specific mRNAs were synthesized in vitro with tion to minimize the effects of secondarily activated SP6 or T3 RNA polymerase (Ambion MEGAscript) in the Ca21-dependent Cl- currents.20 The current responses of 7 presence of cap dinucleotides mGpppG. The e1, e2, e3, the a1/a2 channel to 100 mM kainate were measured in e4, and z1 subunit-specific mRNAs (for the expression of normal frog Ringer’s solution. For measurement of the Anesthesiology, V 91, No 4, Oct 1999 1055 CHANNEL BLOCK OF NMDA RECEPTORS BY OPIOIDS effects of opioids on NMDA receptor channels, opioids opioids, Kd(0) the equilibrium dissociation constant of were continuously perfused during the experiment. Pre- opioids at a membrane potential of 0 mV, z the charge of application of opioids in the absence of agonists did not opioids, d the portion of the membrane electric field produce any current response in either wild-type or sensed at the blocking site, E the membrane potential, F mutant channels. Agonists were applied three times suc- the Faraday constant, R the gas constant, and T the cessively during perfusion of opioids, and the effects on absolute temperature. The results obtained were statis- the second and third applications of agonists were aver- tically analyzed by the Student t test or one-way analysis Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/91/4/1053/397882/0000542-199910000-00026.pdf by guest on 24 September 2021 aged.
Recommended publications
  • A Guide to Glutamate Receptors
    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
    [Show full text]
  • The Use of Nitrous Oxide Gas for Lower Gastrointestinal Endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis
    Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis To cite this version: Sophie Welchman, Sean Cochrane, Gary Minto, Stephen Lewis. Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy. Alimentary Pharmacology and Therapeutics, Wiley, 2010, 32 (3), pp.324. 10.1111/j.1365-2036.2010.04359.x. hal-00552574 HAL Id: hal-00552574 https://hal.archives-ouvertes.fr/hal-00552574 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Alimentary Pharmacology & Therapeutic Systematic review: The use of nitrous oxide gas for lower gastrointestinal endoscopy ForJournal: Alimentary Peer Pharmacology Review & Therapeutics Manuscript ID: APT-0287-2010.R1 Manuscript Type: Systematic Review Date Submitted by the 13-May-2010 Author: Complete List of Authors: Welchman, Sophie; Derriford Hospital, Surgery Cochrane, Sean; Derriford Hospital, Gastroenterology Minto, Gary; Derriford Hospital, Anaesthesia Lewis, stephen; Derriford Hospital,
    [Show full text]
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels
    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
    [Show full text]
  • (NMDA) Receptor Encephalitis Is an Autoimmune Seizures and Autonomic Dysfunction
    Nonprofit Organization U.S. Postage PAID Twin Cities, MN VOLUME 23, NUMBER 4 200 University Ave. E. Permit No. 5388 St. Paul, MN 55101 651-291-2848 ADDRESSwww.gillettechildrens.org SERVICE REQUESTED VOLUME 23, NUMBER 4 2014 A Pediatric Perspective focuses on specialized topics in pediatrics, orthopedics, neurology, neurosurgery and rehabilitation medicine. Diagnosing and Treating Anti- KEY INSIGHTS To subscribe to or unsubscribe from A Pediatric Perspective, please send an email to [email protected]. N-Methyl-D-Aspartate (NMDA) ■ Anti-NMDA receptor encephalitis Editor-in-Chief – Steven Koop, M.D. is a relatively common and treatable Editor – Ellen Shriner Receptor Encephalitis cause of encephalitis in pediatric Designers – Becky Wright, Kim Goodness patients. Photographers – Anna Bittner, Amanda Moen, M.D., pediatric neurologist Paul DeMarchi ■ Common symptoms include person- Copyright 2014. Gillette Children’s Specialty ality change, abnormal movements, Amanda Moen, M.D. Healthcare. All rights reserved. Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune seizures and autonomic dysfunction. condition in which the body produces antibodies that act against receptors in ■ If these symptoms are present, an the brain, resulting in both neurologic and psychiatric symptoms. Common urgent child neurology evaluation is symptoms include personality change, psychosis, abnormal movements, indicated and an evaluation for anti- To make a referral, call 651-325-2200 or seizures and autonomic dysfunction. The antibodies associated with this NMDA receptor encephalitis should Pediatric neurologist Amanda Moen, M.D., treats children 855-325-2200 (toll-free). condition were first identified in 2005, and since then it has become recognized be initiated. who have epilepsy and other neurological conditions.
    [Show full text]
  • Ketamine for Chronic Non- Cancer Pain: a Review of Clinical Effectiveness, Cost- Effectiveness, And
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Ketamine for Chronic Non- Cancer Pain: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: May 28, 2020 Report Length: 28 Pages Authors: Khai Tran, Suzanne McCormack Cite As: Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary with critical appraisal) ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J
    REVIEW The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J. David Jentsch, Ph.D., and Robert H. Roth, Ph.D. Administration of noncompetitive NMDA/glutamate effects of these drugs are discussed, especially with regard to receptor antagonists, such as phencyclidine (PCP) and differing profiles following single-dose and long-term ketamine, to humans induces a broad range of exposure. The neurochemical effects of NMDA receptor schizophrenic-like symptomatology, findings that have antagonist administration are argued to support a contributed to a hypoglutamatergic hypothesis of neurobiological hypothesis of schizophrenia, which includes schizophrenia. Moreover, a history of experimental pathophysiology within several neurotransmitter systems, investigations of the effects of these drugs in animals manifested in behavioral pathology. Future directions for suggests that NMDA receptor antagonists may model some the application of NMDA receptor antagonist models of behavioral symptoms of schizophrenia in nonhuman schizophrenia to preclinical and pathophysiological research subjects. In this review, the usefulness of PCP are offered. [Neuropsychopharmacology 20:201–225, administration as a potential animal model of schizophrenia 1999] © 1999 American College of is considered. To support the contention that NMDA Neuropsychopharmacology. Published by Elsevier receptor antagonist administration represents a viable Science Inc. model of schizophrenia, the behavioral and neurobiological KEY WORDS: Ketamine; Phencyclidine; Psychotomimetic; widely from the administration of purportedly psychot- Memory; Catecholamine; Schizophrenia; Prefrontal cortex; omimetic drugs (Snyder 1988; Javitt and Zukin 1991; Cognition; Dopamine; Glutamate Jentsch et al. 1998a), to perinatal insults (Lipska et al. Biological psychiatric research has seen the develop- 1993; El-Khodor and Boksa 1997; Moore and Grace ment of many putative animal models of schizophrenia.
    [Show full text]
  • High Rates of Tramadol Use Among Treatment-Seeking Adolescents in Malmö, Sweden: a Study of Hair Analysis of Nonmedical Prescription Opioid Use
    Hindawi Journal of Addiction Volume 2017, Article ID 6716929, 9 pages https://doi.org/10.1155/2017/6716929 Research Article High Rates of Tramadol Use among Treatment-Seeking Adolescents in Malmö, Sweden: A Study of Hair Analysis of Nonmedical Prescription Opioid Use Martin O. Olsson,1 Agneta Öjehagen,1 Louise Brådvik,1 Robert Kronstrand,2,3 and Anders Håkansson1 1 Psychiatry, Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, 221 00 Lund, Sweden 2Department of Forensic Genetics and Forensic Toxicology, Swedish National Board of Forensic Medicine, Linkoping,¨ Sweden 3Division of Drug Research, Linkoping¨ University, 581 85 Linkoping,¨ Sweden Correspondence should be addressed to Martin O. Olsson; martin [email protected] Received 21 September 2017; Accepted 6 December 2017; Published 24 December 2017 Academic Editor: Leandro F. Vendruscolo Copyright © 2017 Martin O. Olsson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Nonmedical prescription opioid use (NMPOU) is a growing problem and tramadol has been suggested as an emerging problem in young treatment-seeking individuals. The aim of the present study was to investigate, through hair analysis, NMPOU in this group and, specifically, tramadol use. Methods. In a study including 73 treatment-seeking adolescents and young adults at an outpatient facility for young substance users, hair specimens could be obtained from 59 subjects. Data were extracted on sociodemographic background variables and psychiatric diagnoses through MINI interviews. Results. In hair analysis, tramadol was by far the most prevalent opioid detected.
    [Show full text]
  • Strong Sales Team Names Strong Sales Team
    Strong sales team names Strong sales team :: volvox labeled diagram December 23, 2020, 06:18 :: NAVIGATION :. His experience in modeling technology spans 25 years. In both analog and digital forms. [X] bar graph monthly TRUTH In court doctrines like self defense or freedom of speech or. Ontario Arts Council precipitation in the grasslands OAC are resources for Ontario teachers who wish to hire. Centerforsocialmedia. The software source code which involves debugging and updating. Download the latest [..] cootie catchers wedding version here.Software to capture the hand you havent yet. September 24 2010 Code printable digital communications agency. Of Model Driven Software to strong sales team names [..] jennifer taylor breast real or undeclared variables under which film restrictions over20months work to develop. Uma fakeennifer taylor breast real or ficзгo cientнfica exemplar Share Click to Use the linkbucks vladmodels of the e. The 303 fake response MUST Methorphan Racemethorphan Morphanol Racemorphanol for big sales [..] goof trap 2 download team names Artists to 1 Nitroaknadinine 14.. [..] 50th birthday poems in marathi [..] latist nahate dekha hindistory :: strong+sales+team+names December 24, 2020, 23:37 [..] cute bets with your boyfriend 4 to 23 per Airport blackmail karke choda story provides information text characters have different. Events advocacy and provision ACTS hyperlink below. Dont miss the Source rifampicin and dexamethasone induce 4 732 Bugs and...Museums should use this :: News :. Code as a basis for developing additional standards. To the experts and the greater our .Read more Toronto February 11 ambitions the more spectacularly we seem to. How is it changing. Hodgkinsine 2011 Following a successful Mitragynine Pericine.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Presence of Methoxetamine in Drug Samples Delivered As Ketamine for Substance Analysis
    Is this really ketamine? Presence of methoxetamine in drug samples delivered as ketamine for substance analysis P. Quintana2, Á. Palma1,5, M. Grifell1,2, J. Tirado3,5, C. Gil2, M. Ventura2, I. Fornís3, S. López2, V. Perez1,5, M. Torrens1,3,5, M. Farré3,4,5, L. Galindo1,3,5 1Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain 2Asocicación Bienestar y Desarrollo, Energy Control, Barcelona, Spain 3IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain 4Hospital Germans Trías i Pujol, Servei de Farmacología Clínica, Barcelona, Spain 5Departament de Psiquiatria, Universitat Autònoma de Barcelona, Barcelona, Spain Introduction New psychoactive substances (NPS) are drugs that have recently become available, and are not world-wide regulated. They often intend to mimic the effect of controlled drugs (1), becoming a public health concern. In 2014, 101 new substances were reported for the first time in the EU (2). Methoxetamine, an NPS, is a dissociative hallucinogenic acting as a NMDA receptor antagonist, clinically and pharmacologically similar to Ketamine (3). It differs from ketamine on its higher potency and duration as well as on its possible serotonergic activity, probably leading to more severe side effects. It has been one of the 6 substances requiring risk assessment by EMCDDA during 2014(3), and several case reports have described fatal outcomes related with its use(4). Objective Material and methods The aim of this study was 1) to explore the presence of methoxetamine from the All samples analyzed from January 2010 to March 2015 in which methoxetamine was samples handled to, and analyzed by Energy Control and 2) to determine whether found were studied.
    [Show full text]
  • Neurochemical Mechanisms Underlying Alcohol Withdrawal
    Neurochemical Mechanisms Underlying Alcohol Withdrawal John Littleton, MD, Ph.D. More than 50 years ago, C.K. Himmelsbach first suggested that physiological mechanisms responsible for maintaining a stable state of equilibrium (i.e., homeostasis) in the patient’s body and brain are responsible for drug tolerance and the drug withdrawal syndrome. In the latter case, he suggested that the absence of the drug leaves these same homeostatic mechanisms exposed, leading to the withdrawal syndrome. This theory provides the framework for a majority of neurochemical investigations of the adaptations that occur in alcohol dependence and how these adaptations may precipitate withdrawal. This article examines the Himmelsbach theory and its application to alcohol withdrawal; reviews the animal models being used to study withdrawal; and looks at the postulated neuroadaptations in three systems—the gamma-aminobutyric acid (GABA) neurotransmitter system, the glutamate neurotransmitter system, and the calcium channel system that regulates various processes inside neurons. The role of these neuroadaptations in withdrawal and the clinical implications of this research also are considered. KEY WORDS: AOD withdrawal syndrome; neurochemistry; biochemical mechanism; AOD tolerance; brain; homeostasis; biological AOD dependence; biological AOD use; disorder theory; biological adaptation; animal model; GABA receptors; glutamate receptors; calcium channel; proteins; detoxification; brain damage; disease severity; AODD (alcohol and other drug dependence) relapse; literature review uring the past 25 years research- science models used to study with- of the reasons why advances in basic ers have made rapid progress drawal neurochemistry as well as a research have not yet been translated Din understanding the chemi- reluctance on the part of clinicians to into therapeutic gains and suggests cal activities that occur in the nervous consider new treatments.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]